Eli Lilly SWOT Analysis
The pharmaceutical company that won the incretin market, now converting that win into a much larger and much cheaper one. Q1 2026 revenue rose 56% to $19.8B — driven by volume and, per Lilly's own release, 'partially offset by lower realized prices' for Mounjaro and Zepbound — with reported EPS up 170% to $8.26 and non-GAAP EPS up 156% to $8.55. Mounjaro delivered $8.7B (+125%) and Zepbound $4.2B (+80%), a combined $12.8B in a single quarter, and management raised full-year 2026 guidance by $2B to $82.0-85.0B of revenue and $35.50-37.00 of non-GAAP EPS. Lilly also settled the efficacy argument outright: in a head-to-head Phase 3, its tirzepatide produced a 25.5% body-weight reduction over 84 weeks against 23% for Novo Nordisk's CagriSema, knocking roughly 15% off Novo's share price. And the FDA approved Foundayo (orforglipron), described as the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. This SWOT centers on the 'Oral Conversion Test' — Lilly is deliberately migrating from a high-price, injection-willing, largely commercial market into a low-price, policy-subsidized mass market ($149-per-month oral starting doses via Medicare, Medicaid or TrumpRx, $50 monthly Medicare copays, and roughly 15 million newly eligible patients as Medicare obesity coverage opens mid-2026), so the test is arithmetic: does patient volume grow faster than realized price per patient falls? Q1 already contains both forces. Reports Q2 2026 on August 5, 2026.
PharmaceuticalsLast edited 2026-07-27
★ 重要ポイント
- 1最大の強み — Growth That Barely Looks Real: Q1 2026 revenue of $19.8 billion grew 56% year over year, reported EPS rose 170% to…
- 2最大の弱み — One Molecule Carries the Company: Mounjaro and Zepbound are both tirzepatide, together delivering $12.8 billion in a…
- 3最大の機会 — Medicare Opens a 15-Million-Patient Pool: Medicare began covering obesity drugs for some patients in mid-2026 — the…
Eli Lilly SWOTスナップショット
| カテゴリ | 主な要因（上位3件） |
|---|---|
| 強み |
|
| 弱み |
|
| 機会 |
|
| 脅威 |
|
The SWOT
every quadrant, every point ↘Eli Lillyの強み（2026年）
7Growth That Barely Looks Real: Q1 2026 revenue of $19.8 billion grew 56% year over year, reported EPS rose 170% to $8.26, non-GAAP EPS rose 156% to $8.55, and full-year guidance was raised by $2 billion mid-year to $82.0-85.0 billion.
The Incretin Franchise at Scale: Mounjaro generated $8.7 billion in worldwide Q1 revenue (up 125%) and Zepbound $4.2 billion (up 80%) — a combined $12.8 billion in a single quarter.
The Best Molecule, Confirmed Head-to-Head: In a direct Phase 3 comparison, tirzepatide delivered a 25.5% body-weight reduction over 84 weeks against 23% for Novo Nordisk's CagriSema — a comparative endpoint rather than a cross-trial marketing claim, and the reason prescribers and payers have a defensible reason to default to Lilly.
First to an Unconstrained Oral: The FDA approved Foundayo (orforglipron) for adults with obesity or overweight with weight-related medical problems — described as the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions, a major adherence advantage in chronic self-administered therapy.
Small-Molecule Manufacturing Advantage: An oral small molecule is fundamentally easier to produce and distribute at scale than an injectable peptide, which is what makes serving a Medicare-expanded market at $149 per month economically conceivable at all.
Cash Flow to Fund Everything at Once: Growth of this magnitude simultaneously funds manufacturing build-out, adjacent-indication trials and business development — the compounding advantage of winning a category while it is still expanding.
Global Commercial Infrastructure and Prescriber Credibility: A worldwide sales and distribution network plus decades of prescriber relationships let Lilly launch and scale new formulations faster than a challenger can build equivalent reach.
Eli Lillyの弱み（2026年）
7One Molecule Carries the Company: Mounjaro and Zepbound are both tirzepatide, together delivering $12.8 billion in a single quarter and the overwhelming majority of incremental revenue — every safety signal, supply interruption, reimbursement decision or patent question lands on a single narrow base.
Realized Prices Are Already Falling: This is not a forecast but a disclosure — Lilly's own Q1 release attributes 56% growth to volume 'partially offset by lower realized prices' for Mounjaro and Zepbound, meaning the price reset began before the oral market did.
Scale Execution Risk in the Oral Era: Serving a Medicare-expanded oral population requires manufacturing and distributing at volumes well beyond the injectable era, and in a market where a competitor pill exists, any capacity shortfall converts immediately into ceded share rather than deferred revenue.
A Cardiometabolically Concentrated Pipeline: Lilly holds real assets outside metabolic disease, but the pipeline's center of gravity is cardiometabolic, leaving less than more broadly diversified large-cap peers to absorb a category-level shock.
Permanent Pricing-Politics Exposure: Obesity therapeutics are now an explicit political subject, with pricing negotiated at the level of national policy rather than payer contracts — a structural feature of the revenue line from here on.
Biologics Supply Complexity: Complex manufacturing for injectable biologics creates supply-chain and quality-management vulnerability that persists even as the oral portfolio grows.
Reimbursement Fragmentation: Coverage gaps between Medicare, Medicaid, commercial plans, cash-pay and direct-to-consumer channels create friction between approved demand and realized revenue.
Eli Lillyの機会（2026年）
7Medicare Opens a 15-Million-Patient Pool: Medicare began covering obesity drugs for some patients in mid-2026 — the first time ever — with certain patients paying $50 per month across all approved injectable and oral GLP-1 uses, a change analysts estimate could add roughly 15 million eligible patients and pull private insurers along behind it.
Oral Removes the Injection Barrier: The largest constraint on GLP-1 adoption has never been efficacy but willingness to inject weekly; an unconstrained daily pill addresses a population multiples larger than the injectable market, which is the entire strategic bet.
Adjacent Indications on the Same Molecule: Cardiovascular risk reduction, sleep apnea, MASH, and type 2 diabetes with elevated cardiovascular risk each extend the franchise into newly reimbursed populations without a new discovery cycle — Lilly has already reported positive Phase 3 data for orforglipron in type 2 diabetes with obesity or overweight at increased cardiovascular risk.
A Path Toward Roughly $94 Billion: With FY2026 guidance at $82-85 billion, the widely discussed path toward roughly $94 billion rests specifically on the oral obesity market executing.
International Penetration: Under-served markets with rising diabetes and obesity prevalence remain largely untapped, and a shelf-stable pill is far easier to distribute internationally than a cold-chain injectable.
Manufacturing Investment as Competitive Weapon: Aggressive capacity build-out converts supply into share in a market where demand consistently exceeds available product.
Direct-to-Consumer Channels: TrumpRx.gov and Lilly's own direct channels create a route to patients that bypasses some payer friction, at a transparent price point.
Eli Lillyの脅威（2026年）
7A Structural, Policy-Set Price Reset: $149-per-month oral starting doses, $50 Medicare copays, most-favored-nation pricing and direct-to-consumer discounting through TrumpRx.gov together reset realized revenue per patient downward — permanently, and outside Lilly's control.
CagriSema Still Reaches the Market: Losing the head-to-head cost Novo its narrative, not its filing — CagriSema is still expected to win FDA approval in late 2026 on its REDEFINE 1 and 2 placebo data, and a second approved combination expands payer leverage even where it is not the efficacy leader.
Novo's Oral Counterattack: Novo is leaning on its newly launched Wegovy pill to stabilize declining share while absorbing most-favored-nation pricing pressure and nearing patent expirations — a cornered incumbent with an approved oral is a price competitor, and price is where the new market is fought.
Next-Generation Entrants: Amgen, Viking Therapeutics and others are advancing obesity assets into a market that is now proven, reimbursed and enormous — precisely the conditions that attract the most capital.
Manufacturing Disruptions: Any interruption in complex supply chains for either the injectable or oral portfolio converts directly into unmet demand in a category with credible substitutes.
Patent Cliffs and Biosimilars: Tirzepatide's eventual exclusivity expiry plus biosimilar competition across the broader portfolio threaten established revenue on a defined clock.
Regulatory and Trial Risk: Delays in approvals for new indications or next-generation formulations would slow exactly the adjacent-indication expansion the growth case depends on.
TOWS Strategy Matrix
PROFrom insight to action — pairing the four quadrants into concrete strategies.
SOGrowthStrengths × Opportunities
Convert Efficacy Leadership Into Oral Volume: Use the 25.5%-versus-23% head-to-head win and prescriber credibility (Strength) to make Foundayo the default oral as Medicare coverage opens to roughly 15 million patients (Opportunity).
Scale the Pill Because You Can: Use the small-molecule manufacturing advantage (Strength) to serve the mass oral market at $149-per-month starting doses (Opportunity) at volumes an injectable never could.
Fund Adjacent Indications From the Franchise: Use $12.8 billion of quarterly incretin revenue (Strength) to finance cardiovascular, sleep-apnea and MASH programs on the same molecule (Opportunity).
Take the International Market With a Shelf-Stable Product: Use global commercial infrastructure (Strength) plus an oral formulation to penetrate under-served markets (Opportunity) without cold-chain constraints.
Reinvest the Guidance Raise: Use raised $82-85 billion guidance and cash generation (Strength) to accelerate capacity ahead of demand (Opportunity), making supply a weapon rather than a ceiling.
WOTurnaroundWeaknesses × Opportunities
Outgrow the Price Reset With Volume: Address falling realized prices (Weakness) by converting Medicare eligibility into initiated, persistent therapy at scale (Opportunity) so total revenue compounds anyway.
Diversify Off One Molecule: Reduce tirzepatide concentration (Weakness) by expanding into cardiometabolic and non-metabolic adjacent indications (Opportunity) that broaden the revenue base.
Build Oral Capacity Ahead of Demand: Address oral-era scale execution risk (Weakness) with aggressive manufacturing investment and partnerships (Opportunity) before a competitor pill can fill the gap.
Use Direct Channels to Bypass Payer Friction: Counter reimbursement fragmentation (Weakness) with TrumpRx and direct-to-consumer routes (Opportunity) that reach patients at a transparent price.
Balance the Pipeline While Growth Is Cheap: Offset cardiometabolic concentration (Weakness) by funding non-metabolic programs now (Opportunity), while the incretin franchise can pay for them.
STDefenseStrengths × Threats
Defend on Efficacy Where Price Is Equal: Use the confirmed 25.5% head-to-head advantage (Strength) to hold premium positioning against CagriSema's late-2026 arrival and Novo's Wegovy pill (Threat).
Win the Cost Curve: Use small-molecule economics (Strength) to stay profitable at policy-set prices (Threat) that squeeze competitors with worse cost structures.
Make Supply the Moat: Use cash flow and manufacturing scale (Strength) to ensure capacity is never the reason a competitor's pill gets written (Threat).
Extend Exclusivity With Evidence: Use clinical-evidence depth and outcomes data (Strength) to defend against patent cliffs and biosimilars (Threat) through new indications, formulations and combinations.
Hold Prescriber Defaults: Use decades of prescriber relationships (Strength) to keep Lilly the first-line choice as new entrants arrive with capital but no track record (Threat).
WTRetreatWeaknesses × Threats
Plan for Price-Down, Volume-Up: Manage falling realized prices (Weakness) against the policy-set reset (Threat) by modelling margin per patient at $149 rather than at legacy commercial pricing.
Reduce Single-Molecule Fragility: Given tirzepatide concentration (Weakness) and intensifying competition (Threat), accelerate portfolio breadth so no single molecular setback is existential.
Protect Against Supply-Driven Share Loss: Given oral scale-up risk (Weakness) and credible substitutes (Threat), hold redundant capacity even at the cost of near-term efficiency.
Engage Policy Rather Than React: Given permanent pricing-politics exposure (Weakness) and MFN/TrumpRx pressure (Threat), negotiate durable frameworks instead of absorbing repeated ad-hoc resets.
Sequence Adjacent Indications by Probability: Given regulatory and trial risk (Threat) and pipeline concentration (Weakness), prioritize the highest-probability adjacent indications to keep the growth path from resting on one readout.
make it yours ↘
Want to customize this analysis?
Tailor this Eli Lilly SWOT to your specific context — your market, your goals, your strategy.
SISTER SITE · FRAMEWORKLIST.COM
Beyond SWOT: other frameworks to try
SWOT is one of 100+ thinking frameworks on FrameworkList — covering strategy, prioritization, risk, business models, and decision-making.
Strategy
Porter's Five Forces
Map industry rivalry, suppliers, buyers, entrants, substitutes.
Strategy
PESTEL
Scan political, economic, social, technological, environmental, legal forces.
Risk
Pre-mortem
Imagine the failure first, then work backwards to prevent it.
Prioritization
RICE Scoring
Prioritize by reach × impact × confidence ÷ effort.
Business model
Lean Canvas
One-page model for problem, solution, channels, and key metrics.
Goals
OKR
Objectives + measurable Key Results to align teams on outcomes.
よくある質問
Eli LillyのSWOT分析における強みは何ですか？
- Growth That Barely Looks Real: Q1 2026 revenue of $19.8 billion grew 56% year over year, reported EPS rose 170% to $8.26, non-GAAP EPS rose 156% to $8.55, and full-year guidance was raised by $2 billion mid-year to $82.0-85.0 billion.
- The Incretin Franchise at Scale: Mounjaro generated $8.7 billion in worldwide Q1 revenue (up 125%) and Zepbound $4.2 billion (up 80%) — a combined $12.8 billion in a single quarter.
- The Best Molecule, Confirmed Head-to-Head: In a direct Phase 3 comparison, tirzepatide delivered a 25.5% body-weight reduction over 84 weeks against 23% for Novo Nordisk's CagriSema — a comparative endpoint rather than a cross-trial marketing claim, and the reason prescribers and payers have a defensible reason to default to Lilly.
- First to an Unconstrained Oral: The FDA approved Foundayo (orforglipron) for adults with obesity or overweight with weight-related medical problems — described as the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions, a major adherence advantage in chronic self-administered therapy.
- Small-Molecule Manufacturing Advantage: An oral small molecule is fundamentally easier to produce and distribute at scale than an injectable peptide, which is what makes serving a Medicare-expanded market at $149 per month economically conceivable at all.
- Cash Flow to Fund Everything at Once: Growth of this magnitude simultaneously funds manufacturing build-out, adjacent-indication trials and business development — the compounding advantage of winning a category while it is still expanding.
- Global Commercial Infrastructure and Prescriber Credibility: A worldwide sales and distribution network plus decades of prescriber relationships let Lilly launch and scale new formulations faster than a challenger can build equivalent reach.
Eli LillyのSWOT分析における弱みは何ですか？
- One Molecule Carries the Company: Mounjaro and Zepbound are both tirzepatide, together delivering $12.8 billion in a single quarter and the overwhelming majority of incremental revenue — every safety signal, supply interruption, reimbursement decision or patent question lands on a single narrow base.
- Realized Prices Are Already Falling: This is not a forecast but a disclosure — Lilly's own Q1 release attributes 56% growth to volume 'partially offset by lower realized prices' for Mounjaro and Zepbound, meaning the price reset began before the oral market did.
- Scale Execution Risk in the Oral Era: Serving a Medicare-expanded oral population requires manufacturing and distributing at volumes well beyond the injectable era, and in a market where a competitor pill exists, any capacity shortfall converts immediately into ceded share rather than deferred revenue.
- A Cardiometabolically Concentrated Pipeline: Lilly holds real assets outside metabolic disease, but the pipeline's center of gravity is cardiometabolic, leaving less than more broadly diversified large-cap peers to absorb a category-level shock.
- Permanent Pricing-Politics Exposure: Obesity therapeutics are now an explicit political subject, with pricing negotiated at the level of national policy rather than payer contracts — a structural feature of the revenue line from here on.
- Biologics Supply Complexity: Complex manufacturing for injectable biologics creates supply-chain and quality-management vulnerability that persists even as the oral portfolio grows.
- Reimbursement Fragmentation: Coverage gaps between Medicare, Medicaid, commercial plans, cash-pay and direct-to-consumer channels create friction between approved demand and realized revenue.
Eli LillyのSWOT分析における機会は何ですか？
- Medicare Opens a 15-Million-Patient Pool: Medicare began covering obesity drugs for some patients in mid-2026 — the first time ever — with certain patients paying $50 per month across all approved injectable and oral GLP-1 uses, a change analysts estimate could add roughly 15 million eligible patients and pull private insurers along behind it.
- Oral Removes the Injection Barrier: The largest constraint on GLP-1 adoption has never been efficacy but willingness to inject weekly; an unconstrained daily pill addresses a population multiples larger than the injectable market, which is the entire strategic bet.
- Adjacent Indications on the Same Molecule: Cardiovascular risk reduction, sleep apnea, MASH, and type 2 diabetes with elevated cardiovascular risk each extend the franchise into newly reimbursed populations without a new discovery cycle — Lilly has already reported positive Phase 3 data for orforglipron in type 2 diabetes with obesity or overweight at increased cardiovascular risk.
- A Path Toward Roughly $94 Billion: With FY2026 guidance at $82-85 billion, the widely discussed path toward roughly $94 billion rests specifically on the oral obesity market executing.
- International Penetration: Under-served markets with rising diabetes and obesity prevalence remain largely untapped, and a shelf-stable pill is far easier to distribute internationally than a cold-chain injectable.
- Manufacturing Investment as Competitive Weapon: Aggressive capacity build-out converts supply into share in a market where demand consistently exceeds available product.
- Direct-to-Consumer Channels: TrumpRx.gov and Lilly's own direct channels create a route to patients that bypasses some payer friction, at a transparent price point.
Eli LillyのSWOT分析における脅威は何ですか？
- A Structural, Policy-Set Price Reset: $149-per-month oral starting doses, $50 Medicare copays, most-favored-nation pricing and direct-to-consumer discounting through TrumpRx.gov together reset realized revenue per patient downward — permanently, and outside Lilly's control.
- CagriSema Still Reaches the Market: Losing the head-to-head cost Novo its narrative, not its filing — CagriSema is still expected to win FDA approval in late 2026 on its REDEFINE 1 and 2 placebo data, and a second approved combination expands payer leverage even where it is not the efficacy leader.
- Novo's Oral Counterattack: Novo is leaning on its newly launched Wegovy pill to stabilize declining share while absorbing most-favored-nation pricing pressure and nearing patent expirations — a cornered incumbent with an approved oral is a price competitor, and price is where the new market is fought.
- Next-Generation Entrants: Amgen, Viking Therapeutics and others are advancing obesity assets into a market that is now proven, reimbursed and enormous — precisely the conditions that attract the most capital.
- Manufacturing Disruptions: Any interruption in complex supply chains for either the injectable or oral portfolio converts directly into unmet demand in a category with credible substitutes.
- Patent Cliffs and Biosimilars: Tirzepatide's eventual exclusivity expiry plus biosimilar competition across the broader portfolio threaten established revenue on a defined clock.
- Regulatory and Trial Risk: Delays in approvals for new indications or next-generation formulations would slow exactly the adjacent-indication expansion the growth case depends on.
More Examples
B
Blackstone
資産運用
世界最大のオルタナティブ資産運用会社。プライベートエクイティ、不動産、クレジット・保険、ヘッジファンドソリューションにわたり、機関投資家、そして次第に個人投資家に代わって投資する。Q1 2026にBlackstoneは記録的な1兆3040億ドルのAUM（+12%）を達成、フィー稼得AUMは9376億ドル（+9%）、パーマネント資本は5397億ドル（+16%）。分配可能利益は25%増の17.6億ドル（1.36ドル/株）、フィー関連利益は23%増の15.5億ドル。総流入は同四半期685億ドル（LTM 2463億ドル）で、クレジット・保険事業だけで370億ドルを取り込み、AUMを18%増の4575億ドルへ引き上げた。BREITは純流入プラスに回帰（12億ドル調達、+44%、純リターン9.3%、公開REIT指数を約60%上回る）。本SWOTは「ツースピード・テスト」を中心に据える — Blackstoneの速く耐久性のあるフィー・エンジン（何かを売ることに依存しない、パーマネント資本とクレジット上のフィー関連利益）が、遅く循環的な実現化エンジン（低調なM&A/IPOエグジット市場に制約されるキャリードインタレスト）が再加速するのを待つ間、総利益を成長させ続けられるほど速く複利成長できるか。Q2 2026は2026年7月23日に発表。
Read analysis →R(
RTX (Raytheon)
航空宇宙・防衛
世界最大級の航空宇宙・防衛企業（旧Raytheon Technologies）で、3つのフランチャイズ事業を運営する — Pratt & Whitney（ジェットエンジン、GTF）、Collins Aerospace（アビオニクス、機体構造、キャビンシステム）、Raytheon（ミサイル、防空・ミサイル防衛、レーダー）。FY2025純売上は約886億ドル（Pratt & Whitney 329.2億ドル+17.3%、Collins 302.0億ドル+6.8%、Raytheon 280.4億ドル+5.0%）。RTXは記録的な2710億ドルの受注残（+25%）を民間約1620億ドル／防衛約1090億ドルに分割して抱え、Q1 2026はビート＆レイズだった：調整後売上221億ドル（+9%）、調整後EPS 1.78ドル（+21%、コンセンサス1.52ドル）、FY2026ガイダンスを売上925～935億ドル、EPS 6.70～6.90ドル、フリーキャッシュフロー82.5～87.5億ドルへ引き上げ。本SWOTは「デュアルサイクル・テスト」を中心に据える — RTXが民間アフターマーケットのエンジン（Pratt アフターマーケット+19%）と防衛受注残のエンジン（Raytheon +9%オーガニック、マージン+150bp）を同時にフル稼働させられるか、PrattのGTF粉末金属マージン回復をスイング要因として、関税とBoeing/Airbusの生産レートリスクを吸収しつつ。Q2 2026は2026年7月23日に発表。
Read analysis →BO
Blue Origin
航空宇宙・宇宙
ジェフ・ベゾスの宇宙企業。2026年7月に1,300億ドルの評価額で100億ドルを調達 — 約26年の自己資金運営を経て初の外部資金調達ラウンドで、Coatueが約40億ドル、ベゾスが約20億ドルをコミットした。Blue OriginはNew Glennが軌道到達とブースター回収を実証済みで、34億ドルのNASA Blue Moon月着陸船契約とAmazon Kuiperの最大27回の打ち上げを保有し、5,408基のTeraWaveコンステレーションとProject Sunrise宇宙データセンターに大きく賭けている。しかしNew Glennの飛行はわずか3回にとどまり、2026年4月の飛行では顧客の衛星を軌道に取り残し、2026年5月28日にはスタティックファイア試験でブースターNG-4と唯一の軌道打ち上げ台LC-36を破壊した。本SWOTは「スケール前の信頼性テスト」を中心に据える — Blue Originが、いまだ定常的に飛べていないロケットに依存するスケールへの賭け（TeraWave、Project Sunrise、Kuiper、Artemis）を正当化するに足る速さで、New Glennの打ち上げ頻度と信頼性を回復し、規模で約13倍のライバルSpaceXに対抗しつつ1,300億ドルの評価額を裏付けられるか、である。
Read analysis →★ AI AGENT
Analyze any company in 30 seconds
47,000+ analyses created on SWOTPal — yours is next.
Analyze Free →